ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million

Reuters

01/12

ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million

ADMA Biologics Inc. reported preliminary unaudited full year (FY) 2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter (Q4) of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623345-en) on January 12, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2602170055"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602170055\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602170055?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602170055","market":"fut","top_or_hot":-1,"title":"ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics Inc</a>. reported preliminary unaudited full year (FY) 2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter (Q4) of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623345-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-01-12 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADMA\">ADMA Biologics Inc</a>. reported preliminary unaudited full year (FY) 2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter (Q4) of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623345-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLcfXHW:1","article_id":"2602170055","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602170055","pubTimestamp":1768222843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADMA Biologics Inc. reported preliminary unaudited full year  2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter  of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","ADMA":"ADMA Biologics Inc","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"ADMA Biologics公布2025财年收入为5.1亿美元，年终现金为8800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ADMA":0.9},"content_text":"ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million\n    \n\nADMA Biologics Inc. reported preliminary unaudited full year (FY) 2025 total revenue of approximately USD 510-511 million. Year-end 2025 cash holdings grew to around USD 88 million, with an estimated operating cash flow of about USD 40 million generated in the fourth quarter (Q4) of 2025. The company reiterated its guidance for FY 2025 adjusted EBITDA and adjusted net income. ADMA Biologics Inc. expects FY 2026 and FY 2027 revenue to reach approximately USD 635 million and USD 775 million, respectively. Adjusted net income is projected at around USD 255 million in FY 2026 and USD 315 million in FY 2027. Adjusted EBITDA is forecasted to be about USD 360 million in FY 2026 and USD 455 million in FY 2027. The company maintains its long-term target of generating over USD 1.1 billion in annual revenue and more than USD 700 million in adjusted EBITDA by FY 2029.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623345-en) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}